Full Text
EE260 Cost-Effectiveness Analysis of Sacituzumab Govitecan As Second-Line Treatment for Metastatic Triple-Negative Breast Cancer in Japan

Abstract

Authors

M. Yamaguchi T. Maeda K. Morimoto W. Chen K. Moriwaki K. Shimozuma

Back to Volume 26, Supplemental Issue 6S
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×